Cover Image
市場調查報告書

B型肝炎病毒核心抗原 (HBcAg):開發中產品分析

Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365801
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
B型肝炎病毒核心抗原 (HBcAg):開發中產品分析 Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 44 Pages
簡介

本報告提供以B型肝炎病毒核心抗原 (HBcAg)為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

B型肝炎病毒核心抗原 (HBcAg) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Abivax S.A.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Transgene SA
  • VLP Biotech, Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0319TDB

Summary

Global Markets Direct's, 'Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Review, H1 2016', provides in depth analysis on Hepatitis B Virus Core Antigen (HBcAg) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatitis B Virus Core Antigen (HBcAg), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis B Virus Core Antigen (HBcAg)
  • The report reviews Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis B Virus Core Antigen (HBcAg) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis B Virus Core Antigen (HBcAg)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis B Virus Core Antigen (HBcAg) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis B Virus Core Antigen (HBcAg) Overview
  • Therapeutics Development
    • Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Stage of Development
    • Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Therapy Area
    • Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Indication
  • Hepatitis B Virus Core Antigen (HBcAg) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Hepatitis B Virus Core Antigen (HBcAg) - Products under Development by Companies
  • Hepatitis B Virus Core Antigen (HBcAg) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis B Virus Core Antigen (HBcAg) - Companies Involved in Therapeutics Development
    • Abivax S.A.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Transgene SA
    • VLP Biotech, Inc.
  • Hepatitis B Virus Core Antigen (HBcAg) - Drug Profiles
    • ABX-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-4774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis B vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7944 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-1050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis B Virus Core Antigen (HBcAg) - Dormant Projects
  • Hepatitis B Virus Core Antigen (HBcAg) - Featured News & Press Releases
    • Dec 08, 2015: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B
    • Nov 04, 2015: Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
    • May 27, 2015: GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients
    • Apr 23, 2015: Transgene Presents New Data with TG1050, an Immunotherapy Being Developed to Treat Chronic Hepatitis B, at The International Liver Congress 2015
    • Apr 21, 2015: Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection
    • Feb 26, 2015: ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B
    • Jul 01, 2014: Transgene Announces Presentation of Data on TG1050 Immunotherapy against Chronic Hepatitis B
    • Nov 05, 2013: Transgene Announces Data on TG1050 Presented at Recent Medical and Scientific Conferences
    • Apr 29, 2013: Transgene Presents Positive Preclinical Data On TG1050 To Treat Chronic HBV At EASL 2013
    • Apr 08, 2013: Transgene To Present New Data On TG1050 To Treat Chronic Hepatitis B At EASL 2013 Conference
    • Jan 28, 2013: GlobeImmune Initiates Phase Ia Clinical Trial Of GI-13020 In Healthy Volunteers
    • Nov 12, 2012: Inovio Pharma's Hepatitis B Vaccine Demonstrates Potential To Clear Hepatitis B Virus In Liver In Preclinical Study
    • Nov 12, 2012: Inovio Pharma's Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential To Clear HBV In Liver
    • Apr 19, 2012: Transgene's New Therapeutic Vaccine Candidate to Treat Chronic Hepatitis B Reaches Preclinical Proof of Concept
    • Oct 10, 2011: Inovio Pharma And VGX International To Advance Therapeutic Hepatitis C And Hepatitis B Synthetic Vaccines Into Clinical Studies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Abivax S.A., H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by Gilead Sciences, Inc., H1 2016
  • Pipeline by Transgene SA, H1 2016
  • Pipeline by VLP Biotech, Inc., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top